The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 303-308

  Brocks, D R ^a,b,c   Upward, J W ^b   Georgiou, P ^b   Stelman, G ^b,c   Doyle, E ^b,c   Allen, E ^b   Wyld, P ^d   Dennis, M J ^b,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b GLAXOSMITHKLINE   (United Kingdom)

^c The Frythe   (United Kingdom)

^d Inveresk Clinical Research   (United Kingdom)

Author keywords

asthma bronchial; pharmacokinetics; leukotriene antagonist; pranlukast

Indexed keywords

PRANLUKAST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; VOLUNTEER;

ADOLESCENT; ADULT; ASTHMA; CHROMONES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LEUKOTRIENE D4; MIDDLE AGED;

EID: 0030444354     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050202     Document Type: Article

References (16)

1. Frew AJ, Holgate ST (1993) Clinical pharmacology of asthma: implications for treatment. Drugs 46:847-862
2. Chanarin N, Johnston SL (1994) Leukotrienes as a target in asthma therapy. Drugs 47:12-24
3. Fujimura M, Sakahoto S, Kamis Y, Matsuda T (1993) Effect of a leukotriene antagonist ONO 1078 on bronchial hyperresponsiveness in patients with asthma. Respir Med 87:133-138
4. Yamaguchi T, Kohrogi H, Honda I, Kawano O, Sugimoto M, Araki S, Ando M (1992) A novel leukotriene antagonist. ONO-1078, inhibits and reverses human bronchial contraction induced by leukotrienes C4 and D4 and antigen in vitro. Am Rev Respir Dis 146:923-929
5. Dennis M, Minthorn E, Stelman G, Collie H, Wargenau M, Moeller M, Hust R, Georgiou P, Upward J (1994) Effect of food on the absorption of pranlukast in healthy subjects. Pharmacol Res 11 [Suppl]:S-430
6. Park BK (1978) A specific radio immunoassay for 6b hydroxycortisol in human urine. J Steroid Biochem 9:963-966
7. Bruguerolle B, Lemmer B (1993) Recent advances in chronopharmacokinetics: Methodological problems. Life Sci 52:1809-1824
8. Lemmer B, Bruguerolle B (1994) Chronopharmacokinetics: Are they clinically important. Clin Pharmacokinet 26:419-427
9. Ohnhaus EE, Park BK (1979) Measurement of urinary 6β hydroxycortisol excretion as an in vitro parameter in the clinical assessment of the microsomal enzyme induction capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 15:139-145
10. Perucca E, Grimaldi R, Frigo GM, Sardi A, Moenig H, Ohnhaus EE (1988) Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 34:595-599
11. Pichard L, Fahre I, Daujat M, Domergue J, Joyeux H, Maurel P (1992) Effects of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase in primary cultures of human hepatocytes. Mol Pharmacol 41:1047-1065
12. Saenger P (1983) 6β hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther 34:818-821
13. Zhiri A, Wellman-Bednawska M, Siest G (1986) ELISA of 6β hydroxycortisol in human urine: diurnal variations and effects of anti-epileptic therapy. Clin Chim Acta 157:267-276
14. Guengerich FP (1990) Metabolism of ethynylestradiol in humans. Life Sci 47:1981-1988
15. Tucker GT (1992) The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30:550-553
16. Ged C, Rouillon JM, Pichard L, Combalert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P (1989) The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28:373-387